The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC).
Learn more about the CO45042 Krascendo 2 - KRAS G12C-Mutated NSCLC trial or call the Cancer Research Office at Reading Hospital 484-628-8193.
